Mercer Global Advisors
VKTX icon

Mercer Global Advisors’s Viking Therapeutics VKTX Stock Holding History

Mercer Global Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Buy
10,059
+3,373
+50% +$108K ﹤0.01% 2349
2025
Q4 		$235K Buy
+6,686
New +$237K ﹤0.01% 2433
2020
Q2 		– Sell
-10,640
Closed -$50K – 1180
2020
Q1 		$50K Sell
10,640
-740
-7% -$4.55K ﹤0.01% 1051
2019
Q4 		$91K Buy
+11,380
New +$83K ﹤0.01% 1126

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Mercer Global Advisors's VKTX Position: Q1 2026 in Review

Mercer Global Advisors increased its Viking Therapeutics (VKTX) stake by 50% in Q1 2026, buying an estimated $108K and bringing the position to 10,059 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #2349.

Mercer Global Advisors first reported a position in VKTX in Q4 2019 and has held it in 4 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Mercer Global Advisors held 10,059 shares of Viking Therapeutics worth $327K as of Q1 2026.
  • Mercer Global Advisors bought 3,373 Viking Therapeutics shares in Q1 2026, an estimated $108K.
  • Viking Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2349 holding.
  • Mercer Global Advisors first reported a position in Viking Therapeutics in Q4 2019 and has held it in 4 quarters since.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.